Impedimed Limited · ASX:IPD
Impedimed — Bell Potter Healthcare Conference 2022
17 slides from Impedimed's conference presentation, Nov 10, 2022
Slide 1: Bell Potter Conference Presentation
10 November 2022 For personal use only ASX ANNOUNCEMENT Bell Potter Conference Presentation ImpediMed Limited (ASX.IPD), provides the attached presentation for the virtual Bell Potter Healthcare Conference, showcasing the best of Australasia’s small and mid-cap healthcare offering. The dates of the
Slide 2: Forward-Looking Statements
Forward-Looking Statements This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we
Slide 3: SOZO Digital Health Platform
For personal use only ® SOZO Digital Health Platform ASX:IPD impedimed.com Bell Potter Healthcare Conference Investor Presentation 10 NOVEMBER 2022
Slide 4: Disclaimer Forward Looking Statements
Disclaimer Forward Looking Statements For personal use only • The material contained in this document is a presentation of general information about the • Certain statements in this presentation may constitute forward-looking statements or activities of ImpediMed Limited (“ImpediMed”) current as at
Slide 5: Agenda
Agenda For personal use only • Technology Overview • Market opportunity • Adoption • Path to breakeven - Reimbursement - Financial model and tools to accelerate growth • Key Takeaways Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 3
Slide 6: Our Transformation
Our Transformation Medical Device Connected Digital Health Platform For personal use only U400 BIS Device SOZO Platform U400 Cancer Population^ SOZO® Cancer Population^ • ~20 Minute Test • Less than 30 Second Test • Trained Nurse/Therapist • Medical Assistant • Standalone Device • Connected Device •
Slide 7: Connected Digital Health Platform
Connected Digital Health Platform Test patients at any location and allows data access and sharing across the entire healthcare system For personal use only Cloud Access Scalable Test patients at any location Add and move test locations and immediately review without any additional software results
Slide 8: SOZO Digital Health Platform
® SOZO Digital Health Platform SOZO® measures and tracks critical patient data For personal use only • L-Dex® lymphoedema index • HF-DexTM heart failure index • Total body water • Protein and minerals • Extracellular fluid • Basal metabolic rate • Intracellular fluid • Phase angle • Skeletal muscle
Slide 9: Strong Adoption, Validated Technology
Strong Adoption, Validated Technology ~900 410+ SOZO Devices in SOZO Devices For personal use only Core Business used in recent AZ clinical trials 38 2 international drug studies involving 410+ sites in 28 countries evaluating fluid volumes (heart failure & renal failure patients) Proprietary, do no
Slide 10: Record Patient Testing in Q1 FY'23
Record Patient Testing in Q1 FY’23 For personal use only 48,000 SOZO Patient Tests To-Date Indicator of future health of business: (500,000+ on File) • Record results for Patient Tests conducted in the quarter, with 47,000+ tests conducted in Q1 FY23, +28% YOY 36,000 • 500,000+ Patient Tests now com
Slide 11: Financial Results
Financial Results SOZO Revenue $10.6m For personal use only (Excluding Legacy) Total Revenue $34.9m $2,700,000 FY22 +26% YOY Cash Balance* ✓ RECORD YEAR $2,025,000 $9.9m 10+ Quarters 90%+ SaaS Gross Margins SOZO Revenue $1,350,000 FY22 +29% YOY Operating Cashflow** ✓ RECORD YEAR $675,000 160,000+ <$
Slide 12: Reimbursement the key - Dual path approach
Reimbursement the key - Dual path approach For personal use only 1. Private Payor Reimbursement / Coverage 2. NCCN Guidelines® • Case Assistance Program (CAP) continuing to deliver results • NCCN Guidelines inclusion would establish BIS L-Dex as • CAP produces the appeal wins needed to obtain covera
Slide 13: Increasing Monthly Revenue Rates
Increasing Monthly Revenue Rates For personal use only Continue to increase the Average Monthly License Fees for SOZO 75%+↑ • SOZO average monthly license fee increased by 75%+ since launch Average Monthly License Fees • Success has largely been in a pre-reimbursement environment through since launc
Slide 14: SOZO Business Performance
SOZO BUSINESS PERFORMANCE Strength of renewals and low churn helping to drive growth For personal use only • 38% Average Monthly License Fee increase across US renewal contracts in Q1 FY’23 • This is up from the 34% increase achieved in Q4 FY’22 • Expectation for continued renewal increases for this
Slide 15: Focus on large corporate accounts
Focus on large corporate accounts Assembling the tools to accelerate growth Key IDNs, NCCN Institutions or Corporate Accounts added For personal use only or extended in past 2 quarters: • IDN, Corporate Account and NCCN Institution client base expanding: • In 19 of 31 NCCN Institutions • In 16 of th
Slide 16: Key Takeaways
Key Takeaways For personal use only • Transformation to Connected Digital Health Platform complete • Multiple applications addressing significant health care needs • ~$11.0m+ annual revenue run rate with strong growth despite COVID- 19 headwinds • Sound financial position with sufficient resources a
Slide 17: Contact Details
For personal use only Contact Details Investor Relations: Mike Bassett SVP Corporate and Strategic Development mbassett@impedimed.com +61 407 431 432 www.impedimed.com